Clinical trials: IBM
Healthy
Efficacy of a New Delivery System for Beta-hydroxy-beta-methylbutyrate
The proposed study will test efficacy of HMB in free acid gel to decrease muscle damage, diminish inflammatory response, and improve muscle strength recovery following an acute exercise stress.
- Trial name
- NCT01150526
- Testing
- CaHMB, HMB Free Acid Gel
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Metabolic Technologies Inc.
Inclusion Body Myositis, Myotonic Dystrophy
Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders
Currently, there are no standardised fall risk scores or guidelines on when to use appropriate assistive gait devices (AGDs) for people with neuromuscular disorders (NMDs).
- Conditions
- Inclusion Body Myositis, Myotonic Dystrophy, Limb-girdle and Facioscapulohumeral Muscular Dystrophies, Pompe Disease
- Trial name
- FBIndex (NCT06605612)
- Testing
- FBIndex
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- LMU Klinikum
Sporadic Inclusion Body Myositis
Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis
The primary objective of the study is to evaluate the efficacy of REGN2477+REGN1033 in combination on total lean mass, as measured by Dual-energy X-ray absorptiometry (DXA) in patients with sporadic inclusion body myositis…
- Trial name
- NCT03710941
- Testing
- REGN2477+REGN1033
- Sponsor
- Regeneron Pharmaceuticals
Myositis, Inclusion Body
Alemtuzumab to Treat Sporadic Inclusion Body Myositis
This study will examine the safety and effectiveness of alemtuzumab (Campath® (Registered Trademark)) for improving muscle strength in patients with sporadic inclusion body myositis (s-IBM).
- Trial name
- NCT00079768
- Testing
- Alemtuzumab (Campath)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Inclusion Body Myositis
A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis
- Trial name
- NCT05721573
- Testing
- ABC008
- Where
- 45 sites in United States, Australia and 5 more
- Volunteers
- 272 people
- Sponsor
- Abcuro, Inc.
Polymyositis, Dermatomyositis
Anakinra in Myositis
To investigate the effect of the interleukin-1 (IL-1) blocking agent, anakinra, in patients with treatment-resistant inflammatory myopathies.
- Conditions
- Polymyositis, Dermatomyositis, Inclusion Body Myositis
- Trial name
- NCT01165008
- Testing
- Anakinra
- Where
- Sweden
- Sponsor
- Karolinska Institutet
Inflammation;Muscle(S), Oxidative Stress Injury
Effect of 8-week Supplementation With Black Chokeberry on Recovery in Highly Trained Rowers
Purpose: To analyze the effects of 8-week supplementation with anthocyanin compounds contained in black chokeberry (Aronia melanocarpa) on indicators of inflammation and oxidative stress.
- Conditions
- Inflammation;Muscle(S), Oxidative Stress Injury, Permeability; Increased
- Trial name
- NCT06133751
- Testing
- black chokeberry (Aronia melanocarpa)
- Where
- Poland
- Volunteers
- 15 people
- Sponsor
- Poznan University of Physical Education
Type2 Diabetes
Social Network Analysis to Identify Community Health Workers
The objective of this study is to recruit influential community members using Snowball Sampling Methods. Community members identified through social network analysis as influential and well-connected will be trained as community…
- Trial name
- NCT04210024
- Testing
- Diabetes Empowerment Education Program
- Where
- 2 sites in United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Brittany L Smalls
Myositis, Inclusion Body Myositis
Study of Pioglitazone in Sporadic Inclusion Body Myositis
A study looking at the effect of pioglitazone in skeletal muscle of patients with sporadic inclusion body myositis (sIBM).
- Conditions
- Myositis, Inclusion Body Myositis, Muscular Diseases, Musculoskeletal Disease
- Trial name
- NCT03440034
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Johns Hopkins University
Inflammation; Muscle
Effectiveness of Two Different Forms of Marine Oil on Indirect Markers of Muscle Damage and Soreness in Untrained Men
To evaluate the effects of PCSO-524®, and a blend of PCSO-24® (75%) and krill oil (25%) (ESPO-572®), on indirect markers of muscle damage, inflammation and soreness during recovery from muscle damaging exercise in untrained men.
- Trial name
- NCT03760757
- Testing
- ESPO-572®, PCSO-524®
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Indiana University
IBM, Inclusion Body Myositis
Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis
This study will evaluate whether neuromuscular ultrasound and MRI can be used as imaging markers of bulbar involvement and swallowing dysfunction in individuals with inclusion body myositis (IBM).
- Conditions
- IBM, Inclusion Body Myositis, Myopathy, Myositis
- Trial name
- NCT07823101
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Inclusion Body Myositis
Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial
A multicenter, nonrandomized, open-label, uncontrolled clinical extension trial designed to compare the efficacy and safety of early versus delayed start of arimoclomol in the treatment of Inclusion Body Myositis (IBM)
- Trial name
- NCT04049097
- Testing
- Arimoclomol
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 121 people
- Sponsor
- ZevraDenmark
Inclusion Body Myositis
Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells
This is an open-label, single arm study evaluating the safety for patients with Inclusion Body Myositis. A total of 9 subjects will be enrolled in the study.
- Trial name
- NCT04975841
- Testing
- Adipose Derived Regenerative Cells
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Kansas Medical Center
Inclusion Body Myositis
Molecular Profile of the Evolution of Inclusion Body Myositis
This study aims at assessing the gene expression in the muscles of patients suffering from sporadic Inclusion Body Myositis (sIBM) at various stages of the disease, by comparison with muscles of control subject.
- Trial name
- IBM-RNAseq (NCT03299335)
- Testing
- Blood collection
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Inclusion Body Myositis
Study of Arimoclomol in Inclusion Body Myositis (IBM)
Funding Source - FDA Office of Orphan Products Development (OOPD). The purpose of this study is to evaluate the safety and efficacy of the study drug, arimoclomol in IBM patients.
- Trial name
- NCT02753530
- Testing
- Arimoclomol
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 152 people
- Sponsor
- ZevraDenmark
Inclusion Body Myositis
A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)
An open-label, ascending dose study for adult patients with Inclusion Body Myositis (IBM).
- Trial name
- NCT04659031
- Testing
- ABC008
- Where
- 4 sites in Australia
- Volunteers
- 19 people
- Sponsor
- Abcuro, Inc.
Sporadic Inclusion Body Myositis, Inclusion Body Myositis
Sporadic Inclusion Body Myositis Natural History Study
This is a prospective natural history study on patients with clinically defined sIBM. Participants will be assessed every 6 months over two years (five visits total).
- Trial name
- INSPIRE-IBM (NCT05046821)
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of California, Irvine
Overweight and Obesity, Inflammation; Muscle
Influence of Aerobic Training and Weight Loss on Skeletal Muscle Inflammatory Markers and Muscle Protein Balance in Older Adults
It is estimated that 15% of adults aged 60-70 years, and up to 50% of adults aged 80 years and older are affected by sarcopenia-the age related loss of muscle mass and function.
- Conditions
- Overweight and Obesity, Inflammation; Muscle, Sedentary Lifestyle
- Trial name
- NCT03743675
- Testing
- Diet-Induced Weight Loss, Aerobic Exercise Training
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Miami University
IBM, IIM
MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
Myositis diseases are each rare diseases. As in other rare diseases, people living with myositis diseases face physical and psychosocial challenges that may not be recognized in current research priorities.
- Conditions
- IBM, IIM, Myositis, Inflammatory Myopathy
- Trial name
- MIHRA-PRISMS (NCT07374107)
- Testing
- No intervention - qualitative and mixed methods investigations
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Myositis International Health & Research Collaborative Alliance Foundation
Pompe Disease (Late-onset), Inclusion Body Myositis
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
The primary aim of this nationwide, explorative, cross-sectional study in Germany is to characterize the prevalence, severity and quality of musculoskeletal pain in adult patients with late-onset Pompe disease (LOPD).
- Conditions
- Pompe Disease (Late-onset), Inclusion Body Myositis, Spinal Muscular Atrophy Type 3, FSHD
- Trial name
- NCT05272969
- Testing
- Beck depression inventory fast screen (Questionnaire), Brief Pain Inventory (BPI) (Questionnaire), German Pain Inventory (Questionnaire)
- Where
- Germany
- Volunteers
- 95 people
- Sponsor
- LMU Klinikum